Navigation Links
TIGroup Names Dennis M. Smith as Chief Financial Officer
Date:9/26/2007

LOS ANGELES, Sept. 26 /PRNewswire-FirstCall/ -- TIGroup, Inc. (OTC Bulletin Board: TISG), a California-based financial solutions provider to the healthcare industry focused on ambulatory surgical centers (ASCs) and other businesses designed to deliver quality healthcare services outside of traditional hospital settings, today named Dennis M. Smith as the company's chief financial officer. He has served as a director on the company's board since 2001.

Smith was most recently chief executive officer of Cross Shore Acquisition Corporation, a special purpose acquisition company listed on the Alternative Investment Market of the London Stock Exchange. On August 29, 2007, Cross Shore completed the acquisition of Research Pharmaceutical Services, Inc. (RPS), a provider of integrated clinical development solutions to the bio- pharmaceutical industry. Smith continues to serve as a director of RPS.

Prior to Cross Shore, Smith co-founded and served as vice chairman and chief financial officer of Vsource, Inc., the predecessor to TIGroup. Through Vsource Asia, a subsidiary based in Malaysia, Vsource provides business process outsourcing solutions for Fortune 500 and Global 500 companies in the Asia-Pacific region. Following the sale of Vsource Asia in 2004, Smith served as chairman and chief executive officer of Vsource until July 2005. He continues to serve as a non-executive director, consultant and member of the board of Vsource Asia.

Smith lived and worked in Asia for 28 years. Prior to founding Vsource, he co-founded and served as general partner of ChinaVest, one of the earliest and largest independent private equity firms in Asia. In addition, he held senior positions in commercial and investment banking with First Chicago Corp. (now JPMorgan Chase) in Hong Kong, Singapore and the Philippines. He holds an MBA degree from Loyola University of Chicago.

TIGroup CEO David Hirschhorn said, "We are pleased to welcome Dennis to the company. His le
'/>"/>

SOURCE TIGroup, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus
2. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
3. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
4. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
5. Health Minister Wants Names of Uncooperative Hospital Consultants
6. Chinese PLA Names Bogus Army Medical Bodies Selling Fake Drugs
7. Over 50 Vietnamese Girls Faint Due to Mass Hysteria
8. All U.S. States To Begin Names-Based Reporting of HIV Cases by End of 2007
9. Rajasthan Directs Doctors to Prescribe Medicines by Generic Names
10. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
11. Iodex goes to SmithKline Beecham consumer Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 1VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 2VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 1VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 2Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 1Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 2Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 3